FDA orphan drug designation for zenocutuzumab and racemetyrosine: A milestone achievement in drug development for advanced pancreatic cancer

Human epidermal growth factor receptor 2 (HER2) and HER3 are being investigated as potential targets in pancreatic cancer. Credit: Shutterstock + Magic mine.



  • zenocutuzumab and racemetyrosine